stage IIIB mycosis fungoides/Sezary syndrome
Showing 76 - 100 of >10,000
Mycosis Fungoides, Cutaneous T Cell Lymphoma Trial (Low-dose total-skin electron-beam therapy, Phototherapy)
Not yet recruiting
- Mycosis Fungoides
- Cutaneous T Cell Lymphoma
- Low-dose total-skin electron-beam therapy
- Phototherapy
- (no location specified)
Jan 24, 2022
Interleukin (IL) -35 in Mycosis Fungoides:Case Control Study
Recruiting
- Mycosis Fungoides
- Skin biopsy
-
Giza, EgyptCairo University
May 3, 2023
Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma Trial in Worldwide (Brentuximab
Completed
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- +2 more
- Brentuximab Vedotin
- +2 more
-
Los Angeles, California
- +40 more
Dec 16, 2020
Lung Squamous Cell Carcinoma Trial in Yancheng (To explore the efficacy and safety of immune checkpoint inhibitor combined with
Recruiting
- Lung Squamous Cell Carcinoma
- To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
-
Yancheng, Jiangsu, ChinaYancheng Clinical College of Xuzhou Medical University
Mar 21, 2023
NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)
Recruiting
- Non-small Cell Lung Cancer
- SH-1028 tablets
- Placebo SH-1028 tablets
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Oct 6, 2023
Collecting and Storing Blood Samples From Patients With Cancer
Withdrawn
- Brain and Central Nervous System Tumors
- +10 more
- (no location specified)
Sep 20, 2021
SURvival of SEzary Syndrome Over 1998-2020 Period and Its
Not yet recruiting
- Sezary Syndrome
- Cutaneous T Lymphoma
- Standard of care
-
Paris, FranceHôpital Saint-Louis, Service de Dermatologie
Jan 24, 2022
T-Cell Tumor, Lymphoproliferative Disorders Trial in Ann Arbor (Pacritinib)
Not yet recruiting
- T-Cell Neoplasm
- Lymphoproliferative Disorders
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Oct 6, 2022
Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)
Not yet recruiting
- Unresectable Lung Non-Small Cell Carcinoma
- serplulimab plus chemotherapy as conversion treatment
- (no location specified)
Apr 27, 2023
China With Non-Small-Cell Lung Cancer That is Unable to be
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
May 16, 2023
NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Befotertinib + Icotinib placebo
- Icotinib + Befotertinib placebo
-
Beijing, China
- +2 more
Sep 20, 2023
CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides Trial in Duarte
Withdrawn
- CD30-Positive Neoplastic Cells Present
- +6 more
- Brentuximab Vedotin
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 26, 2019
Quality of Life in Cutaneous Lymphoma Patients Using Skindex29
Not yet recruiting
- Cutaneous Lymphoma
- Quality-of-Life Assessment
- Questionnaire Administration
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 23, 2022
NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)
Recruiting
- Non-Small Cell Lung Cancer
- +5 more
- Toripalimab
- +3 more
-
Guanzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023
Cutaneous T-Cell Lymphoma/Mycosis Fungoides Trial in Gdansk (WP1220)
Completed
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
-
Gdansk, PolandMedical University of Gdansk
Jan 8, 2021
Resectable Early-stage Non-small Cell Lung Cancer
Completed
- Non-small Cell Lung Cancer
-
Alexandria, Egypt
- +3 more
Nov 21, 2022
Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)
Not yet recruiting
- Advanced Squamous Non Small Cell Lung Cancer
- AK112, Carboplatin, Paxlitaxel
- Tislelizumab, Carboplatin, Paxlitaxel
- (no location specified)
Apr 21, 2023
Relapsed or Refractory CD30+ Malignancies When Re-treated With
Completed
- Hodgkin Disease
- Lymphoma, T-Cell, Cutaneous
- No Intervention
-
San Bartolome, Alicante, Spain
- +29 more
Jul 28, 2022
NSCLC Trial in Worldwide (RO7247669, Pembrolizumab, Paclitaxel)
Recruiting
- Non-small Cell Lung Cancer
- RO7247669
- +4 more
-
Benowa, Queensland, Australia
- +6 more
Mar 16, 2023
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +35 more
- chemotherapy
- +6 more
-
Duarte, California
- +4 more
Dec 24, 2019
Unresectable Stage IIIB-IV Malignant Melanoma Trial in Japan (Talimogene laherparepvec)
Completed
- Unresectable Stage IIIB-IV Malignant Melanoma
- Talimogene laherparepvec
-
Nagoya-shi, Aichi, Japan
- +8 more
Jan 13, 2023
Melanoma Trial in Wollstonecraft, Cairns (tigilanol tiglate)
Recruiting
- Melanoma
- tigilanol tiglate
-
Wollstonecraft, New South Wales, Australia
- +2 more
Oct 6, 2022
NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,
Not yet recruiting
- Non-small Cell Lung Cancer
- Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
-
Tianjing, Tianjin, ChinaTianjin cancer hospital
Nov 3, 2023